Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 433.81% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald began coverage on Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Trading Up 1.6 %

VYGR opened at $5.62 on Monday. The firm’s 50 day simple moving average is $5.80 and its two-hundred day simple moving average is $6.62. The company has a market capitalization of $307.02 million, a PE ratio of 7.92 and a beta of 0.93. Voyager Therapeutics has a 1-year low of $4.99 and a 1-year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the company posted ($0.59) earnings per share. Equities analysts forecast that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 10,778 shares of company stock valued at $58,548. Insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares during the period. Erste Asset Management GmbH bought a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $6,192,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Voyager Therapeutics by 19.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock worth $1,005,000 after buying an additional 28,333 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after acquiring an additional 3,473 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Voyager Therapeutics by 7.0% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock worth $801,000 after acquiring an additional 9,000 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.